Edwards Lifesciences
American medical technology company
EW NYSE
ISIN US28176E1082 SEC CIK 1099800 LEI YA13X31F3V31L8TMPR58
Follow Edwards Lifesciences
Weekly email: filings, results
Revenue, last quarter
$1.7B
+10.5% vs same quarter last year
Net income
$307.5M
+5.6% vs same quarter last year
EPS, diluted
$0.53
+6% vs same quarter last year
Operating cash flow
$570.3M
−0.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $6.1B | $1.1B |
| FY24 | $5.4B | $4.2B |
| FY23 | $5B | $1.4B |
| FY22 | $4.5B | $1.5B |
| FY21 | $5.2B | $1.5B |
| FY20 | $4.4B | $823.4M |
| FY19 | $4.3B | $1B |
| FY18 | $3.7B | $722.2M |
| FY17 | $3.4B | $583.6M |
| FY16 | $3B | $569.5M |
| FY15 | $2.5B | $494.9M |
| FY14 | $2.3B | $811.1M |
| FY13 | $2B | $389.1M |
| FY12 | $1.9B | $291.5M |
| FY11 | $1.7B | $236.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 78% | 20.8% | 17.7% |
| FY24 | 79.5% | 25.3% | 76.7% |
| FY23 | 80.5% | 26.1% | 28% |
| FY22 | 83.8% | 33.6% | 34.1% |
| FY21 | 76.1% | 32.3% | 28.7% |
| FY20 | 75.4% | 20.5% | 18.8% |
| FY19 | 74.4% | 26.4% | 24.1% |
| FY18 | 74.8% | 20.1% | 19.4% |
| FY17 | 74.5% | 31.7% | 17% |
| FY16 | 73.1% | 25.3% | 19.2% |
| FY15 | 75.2% | - | 19.8% |
| FY14 | 73.1% | - | 34.9% |
| FY13 | 74.7% | - | 19% |
| FY12 | 74.2% | - | 15.3% |
| FY11 | 70.8% | - | 14.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $1.3B |
| FY24 | $289.9M |
| FY23 | $642.8M |
| FY22 | $973.6M |
| FY21 | $1.4B |
| FY20 | $647.3M |
| FY19 | $928.5M |
| FY18 | $688M |
| FY17 | $832.6M |
| FY16 | $528.3M |
| FY15 | $447M |
| FY14 | $939.4M |
| FY13 | $363.7M |
| FY12 | $253.1M |
| FY11 | $231.6M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $893.4M |
| FY24 | $1.2B |
| FY23 | $879.6M |
| FY22 | $1.7B |
| FY21 | $512.8M |
| FY20 | $625.4M |
| FY19 | $263.3M |
| FY18 | $795.5M |
| FY17 | $763.3M |
| FY16 | $662.3M |
| FY15 | $280.1M |
| FY14 | $300.9M |
| FY13 | $496.9M |
| FY12 | $344.1M |
| FY11 | $303.4M |
- Edwards Lifesciences
- Healthcare median
Show the numbers
| Year | Edwards Lifesciences | Healthcare median |
|---|---|---|
| FY25 | 17.7% | −30.6% |
| FY24 | 76.7% | −47% |
| FY23 | 28% | −58% |
| FY22 | 34.1% | −80.4% |
| FY21 | 28.7% | −71.9% |
| FY20 | 18.8% | −62.2% |
| FY19 | 24.1% | −46.3% |
| FY18 | 19.4% | −49.6% |
| FY17 | 17% | −45.9% |
| FY16 | 19.2% | −36% |
| FY15 | 19.8% | −38.4% |
| FY14 | 34.9% | −35.5% |
| FY13 | 19% | −37.1% |
| FY12 | 15.3% | −29.1% |
| FY11 | 14.1% | −27.9% |